JBIOJade Biosciences, Inc.vs its industry peers
A metric-by-metric comparison of Jade Biosciences, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JBIOThis | $866M#2 | — | 2.0x#3 | — | — | -83.0%#5 | — | -29.0%#4 | — | — | 39.1%#1 | — |
| SVRA | $971M#1 | — | 6.8x#7 | 3777.4x#4 | — | -23.9%#3 | -48072.8%#4 | -82.7%#7 | -93.6%#3 | — | 13.6%#2 | — |
| CRVS | $816M#3 | — | 3.6x#5 | — | — | 75.4%#1 | — | -6.8%#3 | — | — | — | — |
| COLL | $768M#4 | 18.6x#1 | 2.5x#4 | 1.0x#1 | 23.6%#1 | -8.7%#2 | 23.0%#1 | 20.2%#1 | 62.0%#1 | 4#1 | -34.5%#3 | — |
| AKTS | $755M#5 | — | 1.6x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ARDX | $746M#6 | — | 5.0x#6 | 1.8x#2 | 22.1%#2 | -59.0%#4 | -10.1%#2 | -41.6%#5 | -52.3%#2 | — | — | — |
| WVE | $691M#7 | — | 1.7x#2 | 16.2x#3 | -60.5%#3 | -110.7%#6 | -504.1%#3 | -50.9%#6 | — | — | -61.2%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice